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Abstract
Background: Guidelines for initiating ART recommend pregnancy testing, typically a urine test, as part of the basic 
laboratory package. The principal reason for this recommendation is that Efavirenz, a first-line antiretroviral medication, 
has the potential of causing birth defects when used in the first trimester of pregnancy and is therefore contraindicated 
for use by pregnant women. Unfortunately, in many African countries pregnancy tests are not routinely provided or 
available in ART clinics, and, when available outside clinics, are often not affordable for clients.
Recently, the World Health Organization added a family planning job aid called the 'pregnancy checklist,' developed
by researchers at Family Health International, as a recommended tool for screening new ART clients to exclude
pregnancy. Although the checklist has been validated for excluding pregnancy among family planning clients, there
are no data on its efficacy among ART clients.
This study was conducted to assess the clinical performance of a job aid to exclude pregnancy among HIV positive
women initiating ART.
Methods: Non-menstruating women eligible for ART were enrolled from 20 sites in four provinces in Zambia. The 
pregnancy checklist was administered followed by a urine pregnancy test as a reference standard. Sensitivity, 
specificity, and positive and negative predictive values were estimated.
Results: Of the 200 women for whom the checklist ruled out pregnancy, 198 were not pregnant, for an estimated 
negative predictive value of 99%. The sensitivity of the checklist was 90.0%, and specificity was 38.7%. Among the 
women, 416 out of 534 (77.9%) did not abstain from sex since their last menses. Only 72 out of the 534 women (13.4%) 
reported using reliable contraception. Among the 416 women who did not abstain, 376 (90.4%) did not use reliable 
contraception.
Conclusion: The pregnancy checklist is effective for excluding pregnancy in many women initiating ART, but its 
moderate sensitivity and specificity precludes its use to completely replace pregnancy testing. Its use should be 
encouraged in low resource settings where pregnancy tests are unavailable or must be rationed. Family planning 
methods should be available and integrated into ART clinics.
Background
Antiretroviral therapy (ART) has significantly improved
the prognosis of individuals with HIV-1 disease in the
developed world [1-3]. National Zambian ART guidelines
and the World Health Organization (WHO) currently
recommend two nucleosides and two non-nucleosides as
first line regimens in the treatment of HIV patients. Nev-
irapine and Efavirenz are the non-nucleosides of choice
[4,5]. More than 50% of patients on ART are women [6,7]
and it is necessary that their needs are taken into consid-
eration in the provision of care.
Guidelines for initiating ART recommend pregnancy
testing, typically a urine test, as part of the basic labora-
tory package. The principal reason for this recommenda-
tion is that Efavirenz, a first-line antiretroviral
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medication, has the potential of causing birth defects
when used in the first month of pregnancy and is there-
fore contraindicated for use by pregnant women [8].
Though pregnancy tests are supposed to be offered to all
women of reproductive age initiating antiretroviral ther-
apy, the reality in many African countries is that these
tests are not routinely available in ART clinics, or their
price puts them out of reach of many women. As a result,
many women are currently offered treatment without a
pregnancy test, thus compromising the quality of care
offered to women accessing ART services. There is an
urgent need for a tool to help exclude pregnancy in
patient populations where pregnancy tests are often
unavailable. Such a tool, if sufficiently accurate, could also
be used to screen out women who are almost certainly
not pregnant as a means to ration pregnancy test kits in
situations where they are in short supply.
Recently, the WHO added a family planning job aid
called the 'pregnancy checklist,' developed by researchers
at Family Health International, as a recommended tool
for screening new ART clients to exclude pregnancy [9].
The checklist has been validated for excluding pregnancy
among family planning clients in Kenya, Nicaragua, and
Egypt, and has been widely recommended as a tool to
increase access to services [10-12]. In the validation study
conducted in seven clinics in three regions of Kenya, the
estimated negative predictive value was more than 99%
and the estimated specificity was 89% [10]. In the Nicara-
gua and Egypt studies, the estimated negative predictive
values were 100% and 99.6% respectively [11,12]. How-
ever there are no data to demonstrate the checklist's effi-
cacy among ART clients.
The pregnancy checklist consists of six yes/no ques-
tions asked of non-menstruating women about last birth
and menstrual period, duration and frequency of breast-
feeding, recent abortion or miscarriage, abstinence from
sexual relations, and current contraceptive use (Addi-
tional file 1). The questions are based on WHO-approved
criteria [13] and are worded so that a positive response to
any one is sufficient to rule out pregnancy, if the woman
is free of signs or symptoms of pregnancy.
The primary objective of this study was to assess the
clinical performance of the checklist as a screening tool
for excluding pregnancy in women initiating antiretrovi-
ral therapy. A secondary objective was to assess the use of
reliable contraception among this population.
Methods
Study Sites
Four ART sites each from Northern, Northwestern, Lua-
pula, Central and Copperbelt Provinces were selected
making a total of 20 sites. The convenience sample of
sites in each province included urban and rural hospitals
and health centers. Non-menstruating women eligible for
ART in the 20 sites were consecutively enrolled from 1st
March 2009 to 30th June 2009. The pregnancy checklist
was administered to consenting eligible clients followed
by a urine pregnancy test as a reference standard to assess
validity.
Eligibility criteria
All women initiating ART were considered for inclusion.
The criteria for ART initiation were as follows: CD4 less
than 200, WHO Stage IV regardless of CD4, or WHO
Stage III and CD4 less than 350. Women who self-
reported as pregnant, currently menstruating or who
were in WHO Stage I, II, or III with no CD4 count were
excluded from the study.
Sample size calculation
I t was determined that a minimum sample size of 426
would be required to have at least 80% power to reject the
null hypothesis that the negative predictive value is lower
than 98% at the one-sided 5% significance level. This cal-
culation assumes that the true specificity for the checklist
would be 89%, the value observed by Stanback et al. [10],
that the true negative-predictive value would be at least
99.5% in this population, and that the pregnancy rate
would be 2%.
Data collection and entry
After obtaining informed consent, nurses at the ART
clinic administered the checklist to eligible clients and
then performed a urine dipstick pregnancy test. The data
collection forms were reviewed for completeness and
accuracy and then entered in a central Microsoft Access
database. Client information collected included age,
breastfeeding status, parity, CD4 count and menstrual
status. The clients' yes/no responses to the six standard
questions on the checklist were also collected.
Statistical measures, definitions, relevance and analysis
For the purposes of this study, we define sensitivity to be
the proportion of reference test (pregnancy test) positives
for whom the pregnancy checklist would not rule out
pregnancy. We define specificity to be the proportion of
reference test negatives for which the checklist would
rule out pregnancy. We further define the negative pre-
dictive value to be the proportion of patients who have a
negative pregnancy test among those for whom the
checklist would rule out pregnancy, and we define the
positive predictive value to be the proportion of patients
with a positive pregnancy test among those for whom the
checklist would not rule out pregnancy.
The clinically relevant statistic is the negative predictive
value since that statistic reflects the confidence the pro-
vider can have in the checklist's ability to rule out preg-
nancy for a given patient.Torpey et al. BMC Public Health 2010, 10:249
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A cross-classification of patients with respect to preg-
nancy status and checklist result to estimate sensitivity,
specificity, positive and negative predictive values was
used along with exact 90% confidence intervals (two-
sided 90% confidence intervals were used in order to
obtain one-sided 95% lower confidence bounds, which
are equivalent to one-sided tests at the 5% level).
Ethical approval
Ethical Approval was granted by the ERES Converge Eth-
ical Review Board in Lusaka, Zambia and the Protection
of Human Subjects Committee of Family Health Interna-
tional, North Carolina, U.S.A with final clearance from
the Ministry of Health in Zambia.
Results
535 women initiating ART were enrolled into the study.
One was subsequently excluded due to absence of preg-
nancy test results.
Patient characteristics
The mean age of the women was 30.1 yrs with a mean
CD4 count of 148.5 cells/ml. About 55% of the women
were in WHO Stage III, with WHO Stages I and II
accounting for approximately 14% and 19%, respectively.
Twenty-three percent of women had non-postpartum
amenorrhoea most likely due to HIV illness compared to
only 7% with postpartum amenorrhoea. Only 13% of the
patients did not have any children.
Excluding pregnancy
Twenty-two women (4%) were found to be pregnant, for
20 of whom the checklist correctly did not rule out preg-
nancy. Of 200 women for whom pregnancy was ruled out
by the checklist, 198 were in fact not pregnant. (Table 1)
Taking the dipstick pregnancy result as the standard,
the estimated sensitivity of the checklist was 90.9% (exact
90% CI: 74.1%, 98.4%), specificity 38.7% (35.1%, 42.4%),
positive predictive value 6.0% (4.0%, 8.6%), and negative
predictive value 99.0% (96.9%, 99.8%). Based on the esti-
mated lower confidence bound, we can be 95% confident
that the true negative predictive value would be at least
97% in similar populations, but we are unable to reject
the null hypothesis specified for sample size calculations.
Abstinence and use of reliable contraception
About 77.9% (416) of the women did not abstain from sex
since their most recent menses. Only 72 out of the 534
women (13.4%) reported using reliable contraception.
Among the 416 women who did not abstain, 376 (90.4%)
did not use reliable contraception. A majority of the sexu-
ally active women who were not using reliable contracep-
tion were in WHO III (57.9%) or had CD4 less than 200
(77.6%)
Discussion
Excluding pregnancy among women of reproductive age
who present for ART is a challenge, especially in rural
areas where pregnancy test kits may not be easily avail-
able or affordable. In this population of women eligible
for ART, the negative predictive value of the checklist, i.e.,
its ability to accurately clinically rule out pregnancy was
99%. That is, as a clinical screening tool, the checklist was
able to accurately distinguish those women who were
almost certainly not pregnant from those for whom
uncertainty remained; this latter group should be offered
a pregnancy test before being provided with Efavirenz,
but, in the event that pregnancy tests are unavailable,
Nevirapine would be the safer option. Our estimated neg-
ative predictive value is similar to the estimates from ear-
lier studies done in family planning clinics in Kenya,
Nicaragua and Egypt [10-12]. Thus, providers can be
confident when providing ARVs to a woman with a 'Not
Pregnant' result from the checklist. However, fewer
women in this sample of ARV patients met any of the six
criteria that preclude possible pregnancy than in the
Kenya and Egypt studies involving family planning clients
[10,12]. This is likely due to the fact that many new family
planning clients present for services during the extended
postpartum period, and are thus more likely than ARV
Table 1: Comparing checklist results to dipstick pregnancy test.
Checklist Dipstick Test Total
Pregnant Not Pregnant
Pregnancy not ruled out 20 314 334
Pregnancy ruled out 2 198 200
Total 22 512 534
Negative predictive value: 198/200 × 100 = 99.0% Positive predictive value:20/334 × 100 = 6.0%
Sensitivity:20/22 × 100 = 90.9% Specificity:198/512 × 100 = 38.7%Torpey et al. BMC Public Health 2010, 10:249
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patients to be protected from pregnancy either by lacta-
tional infecundability or by postpartum sexual absti-
nence. As a result, the checklist was only able to exclude
pregnancy in 39% of the ARV clients, but even a 39%
reduction is not insignificant from a resource allocation
perspective.
When pregnancy testing presents economic or logistic
difficulties, the pregnancy checklist is a useful tool to
enable correct provision of first line anti-retroviral drugs
for many women. Where pregnancy cannot be ruled out
after the use of the checklist, the health care worker must
either refer the woman for a pregnancy test or avoid regi-
mens containing Efavirenz. This checklist will help clini-
cians make sound clinical decisions and avoid potential
teratogenicity even in the face of severely constrained
resources.
The recent WHO Guidelines recommends initiation of
ART when CD4 is less than 350 cell/ml [4]. CD4 is how-
ever required for stage I and II patients before therapy
can be initiated. The previous guidelines recommended
initiation of therapy in stage IV patients regardless of
CD4, Stage III with CD4 less than 350 and Stage I and II
with CD4 less than 200 [8]. The recent recommendation
will expand the pool of patients with CD4 between 200
and 350. However, this is not expected to change the effi-
cacy the checklist to rule out pregnancy considering the
findings from the family planning clinics in Kenya, Nica-
ragua and Egypt where clients were expected to have
higher CD4. With the reported toxicity in the use of Nev-
irapine in women with CD4 more than 250 [14,15] there
is likely to be an increase in the use of Efavirenz. Tools to
exclude pregnancy before Efavirenz use will be invalu-
able. In addition, the use of the checklist as a screening
tool to exclude pregnancy in women who are already on
Efavirenz and come to the clinic follow up visits, particu-
larly as they become healthier and more sexually active
may be very useful.
One unexpected finding was of the women inter-
viewed; only 13% reported using reliable contraception.
Of those who were sexually active, 90% did not use any
reliable contraception. This finding is important because
prevention of unwanted pregnancies among HIV positive
patients is a major prong in the strategies to prevention of
mother to child transmission. Unfortunately family plan-
ning needs for HIV positive patients are often overlooked
in care and treatment programming.
One study of Rwandan women testing positive for HIV
showed a 30% pregnancy rate. Seventy-four percent of
these pregnancies were unintended, and most of the
women surveyed were not using modern contraception
[16,17]. There is evidence that use of ART may contribute
to increased fertility and fertility desires among HIV pos-
itive women [18-21]. This calls for aggressive and system-
atic integration of family planning services in HIV
prevention, care and treatment services.
There are some limitations to this study. It only
enrolled women who met the MOH program's criteria for
ART eligibility. However, the use of the pregnancy check-
list in asymptomatic HIV positive women may not neces-
sarily have the same negative predictive value. Another
limitation is our use of dipstick pregnancy tests as the ref-
erence or "gold" standard. Such tests are highly accurate
within a week after a missed period, but may not detect
early pregnancies. Finally, because our results were based
on a convenience sample, they may not strictly generalize
to any larger population of women.
Conclusion
The pregnancy checklist is effective in excluding preg-
nancy for many women, and a necessary adjunct to ser-
vices when tests are scarce and/or expensive to help
clinicians prescribe safe first line regimens to women.
However, its moderate sensitivity and specificity preclude
its use to completely replace pregnancy testing. It is
important to integrate and promote use of reliable con-
traception among HIV patients.
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